Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorinostat in Advanced Melanoma
NCT00121225Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Sep 2005
- Primary completion
- Mar 2009
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of vorinostat in melanoma, sponsored by National Cancer Institute. Primary endpoint: Objective Response Rate up to 5 years. Started Sep 2005; status: completed.
02
Drugs
vorinostat
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00121225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00121225.